SYR-472 Open-label Study

Takeda

Status and phase: Completed; Phase 3

Conditions: Diabetes Mellitus

Treatments: Drug: SYR-472

Study type: Interventional

Funder types: Industry

Identifiers

NCT01751360

JapicCTI-122024 (Registry Identifier)

U1111-1137-2768 (Registry Identifier)

SYR-472/OCT-002

Details and patient eligibility

About

To evaluate the efficacy and safety of treatment with SYR-472 in diabetic patients.

Enrollment: 14 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

-1. The participant is judged to be capable of understanding and complying with protocol requirements by the investigator or subinvestigator.

2. The participant can sign and date a written, informed consent form prior to the initiation of any study procedures.

Exclusion criteria

-1. The participant has concurrent serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease

. 2. The participant is assessed to be ineligible for the study by the investigator or subinvestigator.

Trial design

14 participants in 1 patient group

SYR-472 100mg

Experimental group

Description:

SYR-472 100mg

Treatment:

Drug: SYR-472